Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2026-03-10 00:00:00 ET · period of report 2026-03-06 · accession 0001804567-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-10 | 2026-03-06 | SUPN | Mottola Frank | SVP, Chief Tech. Ops. Off | F - Tax | $54.73 | -1,793 | 20.1K | -8% | -$98.1K |
| D | 2026-03-10 | 2026-03-09 | SUPN | Mottola Frank | SVP, Chief Tech. Ops. Off | S - Sale+OE | $53.65 | -1,623 | 18.4K | -8% | -$87.1K |
| D | 2026-03-10 | 2026-03-06 | SUPN | Mottola Frank | SVP, Chief Tech. Ops. Off | M - OptEx | $0.00 | +3,750 | 21.9K | +21% | $0 |
| D | 2026-03-10 | 2026-03-06 | SUPN | Mottola Frank | SVP, Chief Tech. Ops. Off | M - OptEx | $0.00 | -3,750 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-06 | F | D | 1,793 | $54.73 | 20,063 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-09 | S | D | 1,623 | $53.65 | 18,440 | D | — | — | |
| 3 | Common | Common Stock | 2026-03-06 | M | A | 3,750 | $0.00 | 21,856 | D | — | — | |
| 4 | Derivative | Performance Share Unit | 2026-03-06 | M | D | 3,750 | $0.00 | 0 | D | $0.00 · — to — | 3,750 Common Stock | (F2) On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. |